In this study, biologic therapy with both anti-TNFα (ADA, IFX) and non-anti-TNFα (RTX, TCZ) drugs was useful in patients with non-MS ON refractory to systemic glucocorticoids and at least one conventional immunosuppressive drug. The gene discussed is TNF; the disease is myeloid sarcoma.